Alzheimer's Association Statement on European Medicines Agency Negative Opinion on Leqembi for the Treatment of Alzheimer's Disease
July 27, 2024
July 27, 2024
CHICAGO, Illinois, July 27 -- The Alzheimer's Association issued the following statement on July 26, 2024:
* * *
The Alzheimer's Association is disappointed by today's decision by the European Medicines Agency (EMA) to recommend against allowing Leqembi(R) to be marketed across the European Union.
"The EMA has denied people living with Alzheimer's and their families more time," said Joanne Pike, DrPH, Alzheimer's Association president and CEO. &qu . . .
* * *
The Alzheimer's Association is disappointed by today's decision by the European Medicines Agency (EMA) to recommend against allowing Leqembi(R) to be marketed across the European Union.
"The EMA has denied people living with Alzheimer's and their families more time," said Joanne Pike, DrPH, Alzheimer's Association president and CEO. &qu . . .